Latest News

Mar 27, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingVIEW RELEASE
Mar 11, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingVIEW RELEASE
Mar 10, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

Mar 27, 2026 02:28 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

1.27

CHANGE

-0.1 (-6.93%)
Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.